FDA Will Review BLA for Merck’s Bezlotoxumab
On Jan. 27, 2016 FDA announced it plans to review Merck’s investigational antitoxin prevention bezlotoxumab.
Merck announced on Jan. 27, 2016 that FDA will review the biologics license application (BLA) for bezlotoxumab, an investigational antitoxin for prevention of Clostridium difficile (C. difficile) infection recurrence.
There are currently no therapies indicated to prevent C. difficile infection recurrence. Roy Baynes, PhD, senior vice president of clinical development at Merck, said in a statement that C. difficile infection is “one of the most common healthcare-associated infections in US hospitals.”
FDA granted priority review for bezlotoxumab, with a Prescription Drug User Fee Act (PDUFA) action date of July 23, 2016. The company also has filed a marketing authorization application for bezlotoxumab with the European Medicines Agency (EMA) that is currently under review.
Source: Merck
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
